Life Science News

Launches New Website and Marketing Campaign

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced, that in recognizing the business significance of the historic 4:20 World Cannabis Day, its wholly owned subsidiary Sterilumen launched an integrated, multi-touchpoint marketing campaign targeting the $20B North American Cannabis Market.

The Company has also forged a strategic multi-media-platform partnership with Cannabis Business Times to educate growers and operations leaders the criticality of pure, high-quality air in the grow environment. The campaign includes the redesigned and launch of the Airoclean420 website, as well as leads-generation ads on several platforms and advertising across print, e-Newsletter, and digital video and print platforms. In addition, the Company plans to exhibit its Airoclean™ 420 by Sterilumen at the Cannabis Business Times' Cannabis Conference in Las Vegas August 23-25, 2022. The Cannabis marketing initiative marks the first of many planned investments into our three acquired Companies (Akida Holdings, Kes Science and Scientific Air Management) targeting key verticals of growth that we expect to increase brand recognition, drive both market share and top line revenue.

John F. Andrews, Applied UV's Chief Executive Officer commented, "We are proactively pursuing the high growth cannabis market with the launch of this multi-faceted marketing program. Healthy air is an essential element in growing cannabis and can determine whether the yield produced will be a bumper crop or a total flop. Our Airoclean™ 420 by Sterilumen, dramatically improves crop yield by purifying the air in the growing environment by trapping and destroying all airborne powdery mildew and other fungal diseases. We believe there is tremendous opportunity for our solutions to improve the operations of cannabis growers. We are getting this message out to the industry through the launch of the airoclean420 website and other related marketing initiatives."

Airoclean™ 420 by Sterilumen launched in 2015 is a pioneering brand that has been trusted for more than a decade by commercial and home/hobby growers across North America and, is the most effective air purification system in destroying powdery mildew and airborne fungal diseases that ruin cannabis plants and businesses. The cannabis crop is subject to many viruses that could impede growth and destroy crops. Powdery mildew is one of the most potent destroyers of cannabis grows in the world. The pathogen spreads through the air and gets into the vascular system of the plants. It remains hidden until two weeks into flowering before it wreaks havoc on the entire grow. When it is detected, growers must destroy the crop, remove all their equipment, and conduct an intensive and costly deep clean. Certain fungicides can combat powdery mildew, but these are illegal in some states and are of questionable safety given they are sprayed on something intended for human consumption. Airoclean™ 420 by Sterilumen eradicates powdery mildew and other airborne pathogens and not only protects the crops but helps protect the personnel from airborne pathogens working in the facilities growing them as well.

For additional information about the Company's Cannabis products, please visit https://www.airoclean420.com/ .

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® air purification devices are research backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photocatalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following website: https://www.applieduvinc.com/ ;

Forward-Looking Statements

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.

For additional Company Information:

Applied UV Inc.
John F. Andrews
CEO/Director
john.andrews@applieduvinc.com

Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331

News Provided by Business Wire via QuoteMedia

AUVI:NSD
Applied UV

Applied UV


Keep reading...Show less
How Do Medical Devices Get Approved?

How Do Medical Devices Get Approved?

Life science investors are familiar with the arduous path new drugs must go through to reach the market. But how do medical devices get approved?

In terms of devices, the same rigorous testing and inspection are required from regulatory agencies. The US Food and Drug Administration (FDA) is the agency tasked with reviewing new devices and making amendments to already approved devices.

More specifically, medical device approval is done through the FDA’s Center for Devices and Radiological Health (CDRH). The CDRH looks after the entire regulation process for companies that manufacture, repackage, relabel and import devices to the US.

Keep reading...Show less

Danaher Announces Appointment of Feroz Dewan to Danaher Board

Danaher Corporation (NYSE: DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board's Science & Technology Committee. This addition expands the size of Danaher's Board from thirteen to fourteen members.

Mr. Dewan is currently CEO of Arena Holdings Management, a global investment business. From 2003 to 2015, he worked at Tiger Global Management, most recently as Head of Public Equities. Prior to that, Mr. Dewan was a private equity investor at Silver Lake Partners.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Abbott Hosts Conference Call for Second-Quarter Earnings

Abbott (NYSE: ABT) will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022 before the market opens.

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the call will be available later that day.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware

ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware

ALR Technologies SG Pte. Ltd ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, announces the completion of a definitive manufacturing agreement with Infinovo Medical Co. Ltd ("Infinovo") to manufacture and supply the Continuous Glucose Monitor ("CGM") hardware that will be utilized as part of the ALRT GluCurve Pet CGM (the "Manufacturing Agreement"). The Manufacturing Agreement gives ALRT the exclusive global rights to distribute the Infinovo CGM hardware for the animal health market, providing long-term production and supply. Subject to the satisfaction of all closing conditions it is expected that initial deliveries of product by Infinovo will be made during Q4 of 2022

"Executing the Manufacturing Agreement with Infinovo marks another major milestone in our path to commercialization and profitability," comments Sidney Chan, Chairman and CEO of ALRT. "Our next targeted milestone is securing distribution for the ALRT GluCurve Pet CGM. We have been working with many of the largest global distributors and pharmaceutical companies in animal health, evaluating different distribution opportunities ranging from joint venture partnerships to sales and distribution agreements. We believe we have narrowed in on the right company and right deal structure to best bring value to our shareholders and to those who care for diabetic pets. We hope to announce the details of this pivotal next step in the near future."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Bloom Health Partners CEO Andrew Morton

Bloom Health Partners CEO Andrew Morton: We're Executing the Plan That We Promised Investors

Bloom Health Partners CEO Andrew Morton: We're Executing The Plan That We Promised Investorsyoutu.be

Keep reading...Show less

Medtronic Board appoints Lidia Fonseca as a new director

Medtronic plc (NYSE: MDT) today announced that its Board of Directors appointed Lidia Fonseca Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022 . Ms. Fonseca will serve on the Compensation Committee and Science and Technology Committee of the Board.

"We are thrilled to welcome Lidia to Medtronic's Board of Directors," said Geoff Martha , Medtronic chairman and chief executive officer. "She has an impressive history of developing digital healthcare solutions that deliver powerful insights to improve patients' lives. Her extensive knowledge and expertise will provide the Board with an important dimension and a tremendously valuable perspective as we drive toward our bold ambition to become the global leader in healthcare technology."

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×